Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2012

View Archived Issues

Phase II trial investigates effects of axitinib in metastatic melanoma

BioCryst reports on extension phase of BCX-4208 trial

Bristol-Myers Squibb announces planned acquisition

First-in-human data disclosed on ALT-801

Pearl Therapeutics completes phase IIb trials of COPD combination therapy

Otuska launches ophthalmic suspension in Japan

Amicus Therapeutics presents results from phase II study in Fabry's disease

BKM-120 assessed as monotherapy and in combination regimens in metastatic breast cancer

Novel antibacterial agents patented by U.S. universities

Roche prepares new series of phosphodiesterase 10A inhibitors

Abbott Laboratories and Enanta Pharmaceuticals present new HCV NS3 inhibitors

Novel anti-inflammatory agents discovered in U.K.

Afraxis presents new serine/threonine-protein kinase PAK inhibitors

Almirall presents novel phosphodiesterase 4 inhibitors

KalVista Pharmaceuticals and JDRF enter partnership

Endo Pharmaceuticals and BioDelivery Sciences sign agreement for pain therapy

Durect reports topline data on Posidur

Ensemble Therapeutics identifies unique small-molecule IL-17 antagonists

Adherex continues enrollment in phase II eniluracil regimen study

Shigamabs study reaches full enrollment

UCB reports encouraging topline data on Vimpat

Presidio Pharmaceuticals provides update on hepatitis C programs

Idenix Pharmaceuticals reports interim data from IDX-184 study

Leo Pharma in-licenses Virobay product

Rigel Pharmaceuticals advances two lead products to clinic

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...